Antibodies
29 January 2016
Ablynx to receive EU 8 million milestone as Boehringer Ingelheim starts first patient study with a bi-specific nanobody in oncology28 January 2016
CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early26 January 2016
MorphoSys Announces Clinical Milestone for Start of Bayer’s Phase 2 Trial Designed to Support Registration of Anetumab Ravtansine25 January 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis22 January 2016
OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium22 January 2016
BIOCAD Announces the First Trastuzumab Biosimilar Approved by the Ministry of Health of the Russian Federation22 January 2016
Amgen’s Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol21 January 2016
Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and anti-GITR Antibodies21 January 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE™ Technology20 January 2016
Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab20 January 2016
Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL19 January 2016
Allakos Successfully Completes Dosing in Phase 1 Clinical Trial of AK001 and Announces Expansion of its Executive TeamNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports